Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Benatar

Showing results (31-40 of 242) with videos related to

Pageof 25
Sort By:
Neurology|April 27, 2007
Evidence report: the medical treatment of ocular myasthenia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology [RETIRED]Michael Benatar, Henry J Kaminski,
Brain : a Journal of Neurology|April 16, 2022
Pre-symptomatic spinal muscular atrophy: a proposed nosologyRichard S Finkel, Michael Benatar
Journal of Cardiovascular Electrophysiology|August 23, 2007
Treatment of pyridostigmine-induced AV block with hyoscyamine in a patient with myasthenia gravisAnil Gehi, Michael Benatar, Jonathan Langberg
Journal of Child Neurology|January 10, 2008
Levetiracetam versus carbamazepine monotherapy for partial epilepsy in children less than 16 years of ageScott Perry, Philip Holt, Michael Benatar
Muscle & Nerve|October 15, 2009
Reference data for commonly used sensory and motor nerve conduction studiesMichael Benatar, Joanne Wuu, Limin Peng
Muscle & Nerve|March 16, 2013
Opportunity and innovation in studying pre-symptomatic amyotrophic lateral sclerosisMichael Benatar, Joanne Wuu, John Ravits
Muscle & Nerve|October 15, 2009
Developing reference data for nerve conduction studies: an application of quantile regressionLimin Peng, Joanne Wuu, Michael Benatar
The Cochrane Database of Systematic Reviews|January 23, 2009
Treatment for familial amyotrophic lateral sclerosis/motor neuron diseaseMichael Benatar, Jerome Kurent, Dan H Moore
The Lancet. Neurology|December 20, 2024
Amyotrophic lateral sclerosis caused by SOD1 variants: from genetic discovery to disease preventionMichael Benatar, Janice Robertson, Peter Munch Andersen
Muscle & Nerve|November 2, 2022
The best and worst of times in therapy development for myasthenia gravisMichael Benatar, Gary Cutter, Henry J Kaminski
Pageof 25

Showing results (31-40 of 242) with videos related to

Sort By:
Pageof 25
Neurology|April 27, 2007
Evidence report: the medical treatment of ocular myasthenia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology [RETIRED]Michael Benatar, Henry J Kaminski,
Brain : a Journal of Neurology|April 16, 2022
Pre-symptomatic spinal muscular atrophy: a proposed nosologyRichard S Finkel, Michael Benatar
Journal of Cardiovascular Electrophysiology|August 23, 2007
Treatment of pyridostigmine-induced AV block with hyoscyamine in a patient with myasthenia gravisAnil Gehi, Michael Benatar, Jonathan Langberg
Journal of Child Neurology|January 10, 2008
Levetiracetam versus carbamazepine monotherapy for partial epilepsy in children less than 16 years of ageScott Perry, Philip Holt, Michael Benatar
Muscle & Nerve|October 15, 2009
Reference data for commonly used sensory and motor nerve conduction studiesMichael Benatar, Joanne Wuu, Limin Peng
Muscle & Nerve|March 16, 2013
Opportunity and innovation in studying pre-symptomatic amyotrophic lateral sclerosisMichael Benatar, Joanne Wuu, John Ravits
Muscle & Nerve|October 15, 2009
Developing reference data for nerve conduction studies: an application of quantile regressionLimin Peng, Joanne Wuu, Michael Benatar
The Cochrane Database of Systematic Reviews|January 23, 2009
Treatment for familial amyotrophic lateral sclerosis/motor neuron diseaseMichael Benatar, Jerome Kurent, Dan H Moore
The Lancet. Neurology|December 20, 2024
Amyotrophic lateral sclerosis caused by SOD1 variants: from genetic discovery to disease preventionMichael Benatar, Janice Robertson, Peter Munch Andersen
Muscle & Nerve|November 2, 2022
The best and worst of times in therapy development for myasthenia gravisMichael Benatar, Gary Cutter, Henry J Kaminski
Pageof 25